Price movement over the last 24 hours
AdaptHealth Corp vs Bank of New York Mellon Corp — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Bank of New York Mellon Corp trades at $149.76 (market cap $104.95B). The key difference: Bank of New York Mellon Corp is far larger — about 76.1× AdaptHealth Corp's market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BNY | |
|---|---|---|
Market Cap | $1.38B | $104.95B |
Sector | Health | Financials |
52-Week High | $13.38 | $152.91 |
52-Week Low | $8.68 | $92.69 |
Enterprise Value | $3.33B | — |
Dividend Yield | — | 1.39% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
BNY Mellon stock trades at $152.91, up 4.29% on the day, near its consensus price target of $156. The stock shows strong momentum with three consecutive quarterly earnings beats and a bullish technical trend. Recent news highlights a planned 19% dividend increase to $0.63 per share and expansion into digital asset services, reflecting strategic growth initiatives. Revenue has grown steadily from $16.0B in 2022 to $19.8B in 2025, with net income margin improving to 29.21%.
The outlook remains positive with analyst consensus leaning toward 'Hold' but no 'Sell' ratings. Key opportunities include dividend growth and digital finance expansion, while risks involve high investing cash outflows and interest expense pressures. The stock's valuation at a P/E of 18.61 appears reasonable given profitability trends, but investors should monitor execution on capital investments.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →